海西新药(02637.HK)预计10月17日上市 引入Harvest Oriental作为基石

Core Viewpoint - The company, Haixi New Drug, is planning a global offering of 11.5 million H-shares, with a price range of HKD 69.88 to HKD 86.40 per share, aiming to raise approximately HKD 848 million for various purposes including R&D and commercialization [1][4]. Group 1: Company Overview - Haixi New Drug is a commercial-stage pharmaceutical company with integrated R&D, manufacturing, and sales capabilities, focusing on a diverse product portfolio in the fastest-growing therapeutic areas in China [2]. - The company has a product portfolio that includes generic drugs for digestive, cardiovascular, endocrine, neurological, and inflammatory diseases, which collectively account for over 25% of China's pharmaceutical sales in 2023 [2][3]. Group 2: Product Pipeline and Approvals - As of the latest feasible date, the company has received approval for 15 generic drugs from the National Medical Products Administration and has established a pipeline of four innovative drugs [3]. - The innovative drug pipeline includes an oral drug for wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion, along with two other drugs in preclinical stages targeting tumors and respiratory diseases [2]. Group 3: Financial Aspects and Use of Proceeds - The cornerstone investor, Harvest Oriental SP, has agreed to subscribe for approximately USD 22 million worth of shares at a median indicative price of HKD 78.14 per share, totaling 219,120 shares [3]. - The estimated net proceeds of approximately HKD 848 million from the global offering will be allocated as follows: 52% for ongoing R&D investments, 23% for enhancing R&D capabilities and seeking collaborations, 8% for improving commercialization capabilities, 7% for optimizing R&D and production systems, and 10% for working capital and general corporate purposes [4].